
United Therapeutics Corporation
NASDAQ:UTHR
Overview | Financials
Company Name | United Therapeutics Corporation |
Symbol | UTHR |
Currency | USD |
Price | 305.39 |
Market Cap | 13,715,736,758 |
Dividend Yield | 0% |
52-week-range | 221.53 - 417.82 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. |
Website | https://www.unither.com |
About United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD